← The Wire
INCYNasdaq
INCYTE CORP
Services-Commercial Physical & Biological Research · DE · CIK 879169
Incyte Corp develops and commercializes therapies for cancer and other inflammatory diseases
⚡ Elevated coverage
$21.68B
Market cap
$114.66
Last close
+0.8%
1D
+10.6%
5D
1.5M
Volume
Price · last 39 sessions+18.0%
May 4L $92.24 · H $114.66Jun 29
122
Total filings
Jun 22, 2026
Last filing
12/31
Fiscal year end
8-KCompany UpdateJun 22, 20268-KShareholder VoteJun 9, 20268-KCompany UpdateJun 8, 2026DEFA14ADEFA14AMay 27, 2026SC 13D/ASC 13D/AMay 11, 2026DEFA14ADEFA14AApr 28, 2026DEF 14ADEFINITIVE PROXY STATEMENTApr 28, 202610-Q10-QApr 28, 20268-KResults of OperationsApr 28, 20268-KExecutive ChangeMar 30, 20268-KExecutive ChangeMar 26, 20268-KCompany UpdateMar 6, 202610-K10-KFeb 10, 20268-KResults of OperationsFeb 10, 2026SC 13D/ASC 13D/AFeb 10, 20268-KExecutive ChangeDec 12, 202510-Q10-QOct 28, 20258-KResults of OperationsOct 28, 20258-KExecutive ChangeOct 3, 20258-KExecutive ChangeAug 7, 202510-Q10-QJul 29, 20258-KResults of OperationsJul 29, 20258-KExecutive ChangeJun 27, 20258-KExecutive Change · Shareholder VoteJun 11, 20258-KCompany UpdateMay 14, 2025DEFA14ADEFA14AApr 29, 2025DEF 14ADEF 14AApr 29, 202510-Q10-QApr 29, 20258-KResults of OperationsApr 29, 202510-K10-KFeb 10, 20258-KResults of OperationsFeb 10, 20258-KExecutive ChangeJan 10, 2025SC 13GSC 13GNov 8, 202410-Q10-QOct 29, 20248-KResults of OperationsOct 29, 2024SC 13GSC 13GOct 21, 202410-Q10-QJul 30, 20248-KResults of OperationsJul 30, 20248-KMaterial Agreement · New Debt / ObligationJul 3, 20248-KShareholder VoteJun 14, 2024DEFA14ADEFA14AMay 30, 20248-KMaterial Agreement · Reg FD DisclosureMay 13, 202410-Q10-QApr 30, 20248-KResults of OperationsApr 30, 2024DEFA14ADEFA14AApr 29, 2024DEF 14ADEF 14AApr 29, 2024SC 13GSC 13GMar 25, 202410-K/A10-K/AFeb 16, 202410-K10-KFeb 13, 20248-KResults of OperationsFeb 13, 202410-Q10-QOct 31, 20238-KResults of OperationsOct 31, 20238-KExecutive ChangeSep 12, 202310-Q10-QAug 1, 20238-KResults of OperationsAug 1, 20238-KExecutive Change · Shareholder VoteJun 15, 2023DEFA14ADEFA14AJun 7, 20238-KCompany UpdateMay 8, 202310-Q10-QMay 2, 20238-KResults of OperationsMay 2, 2023DEFA14ADEFA14AApr 28, 2023DEF 14AFORM DEF 14AApr 28, 202310-K10-KFeb 7, 20238-KResults of OperationsFeb 7, 202310-Q10-QNov 1, 20228-KResults of OperationsNov 1, 20228-KExecutive ChangeOct 4, 202210-Q10-QAug 2, 20228-KResults of OperationsAug 2, 20228-KShareholder VoteJun 16, 202210-Q10-QMay 3, 20228-KResults of OperationsMay 3, 2022DEFA14ADEFA14AApr 29, 2022DEF 14ADEF 14AApr 29, 20228-KExecutive ChangeApr 21, 2022SC 13GSC 13GFeb 14, 202210-K10-KFeb 8, 20228-KResults of OperationsFeb 8, 20228-KExecutive ChangeJan 14, 202210-Q10-QNov 2, 2021
Insider Activity
In the 90 days to Mar 17, 2026: 5 sold $7.2M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 17, 2026 | Cagnoni Pablo JPresident, R&D | Sell | 18,667 | $94.24 | $1.8M |
| Feb 19, 2026 | Cagnoni Pablo JPresident, R&D | Sell | 18,668 | $100.91 | $1.9M |
| Jan 7, 2026 | Issa Mohamed KhairieEVP, Head of US Oncology | Sell | 10,856 | $109.07 | $1.2M |
| Jan 5, 2026 | Stein Steven HEVP & Chief Medical Officer | Sell | 15,634 | $101.70 | $1.6M |
| Dec 19, 2025 | Tray ThomasPrincipal Accounting Officer | Sell | 2,774 | $100.00 | $277K |
| Dec 18, 2025 | Tray ThomasPrincipal Accounting Officer | Sell | 600 | $98.25 | $59K |
| Dec 17, 2025 | Morrissey Michael JamesEVP, Head of Tech. Operations | Sell | 4,323 | $97.26 | $420K |
| Dec 16, 2025 | Morrissey Michael JamesEVP, Head of Tech. Operations | Sell | 53,175 | $97.29 | $5.2M |
| Dec 16, 2025 | Morrissey Michael JamesEVP, Head of Tech. Operations | Sell | 833 | $97.42 | $81K |
| Dec 11, 2025 | Mayes Patrick AEVP & Chief Scientific Officer | Sell | 255 | $94.94 | $24K |
| Dec 10, 2025 | Mayes Patrick AEVP & Chief Scientific Officer | Sell | 5,553 | $95.58 | $531K |
| Dec 2, 2025 | Stein Steven HEVP & Chief Medical Officer | Sell | 20,105 | $102.51 | $2.1M |
| Dec 1, 2025 | Stein Steven HEVP & Chief Medical Officer | Sell | 2,559 | $102.96 | $263K |
| Nov 24, 2025 | Tray ThomasPrincipal Accounting Officer | Sell | 600 | $103.00 | $62K |
| Nov 21, 2025 | Tray ThomasPrincipal Accounting Officer | Sell | 169 | $102.00 | $17K |
| Nov 17, 2025 | Denton Sheila A.EVP & General Counsel | Sell | 278 | $104.36 | $29K |
| Nov 10, 2025 | Hoppenot HerveDirector | Sell | 187,500 | $105.46 | $19.8M |
| Nov 5, 2025 | Stein Steven HEVP & Chief Medical Officer | Sell | 5,233 | $102.20 | $535K |
| Nov 4, 2025 | Denton Sheila A.EVP & General Counsel | Sell | 598 | $101.36 | $61K |
| Nov 3, 2025 | Heeson LeeEVP, Head of Incyte Intl | Sell | 3,074 | $94.02 | $289K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 9 reputable articles · skews ▲ positive.
MarketWatchIncyte Corp. stock underperforms Monday when compared to competitors14d agoMarketWatchIncyte Corp. stock outperforms competitors on strong trading day18d agoInvestor's Business DailyIncyte Nears Buy Point As $1.25 Billion Acquisition Expands Offerings18d agoMarketWatchIncyte Corp. stock outperforms competitors despite losses on the day21d agoMarketWatchIncyte Corp. stock underperforms Thursday when compared to competitors despite daily gains25d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance